GlaxoSmithKline Has No Genzyme Corporation Interest, Seeks Lower R&D Risk

BOSTON (Reuters) - GlaxoSmithKline Plc says it is not interested in making a counterbid for U.S. biotech company Genzyme Corp and that an acquisition of such size would be disruptive to its own research and development.